Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998–2011

Abstract

r-tPA for AIS has resulted in estimated gains in quality-adjusted life years due to reduction in disability and improvement in functioning since its introduction in 1998.

Aphasia and reperfusion therapies in hyper-acute settings: A scoping review

“…Since the USA Food and Drug Administration (FDA) approval in 1996, there has been a small, yet gradual increase in the utilisation of rtPA for treatment of AIS (Lubeck et al, 2016). Results from the NINDS (1995) Study Group demonstrated that rtPA improved functional outcome after ischaemic stroke when given within three hours of symptom onset.…”

“…In 11 of the studies, follow-up was assessed with the modified Rankin Scale (mRS) ( Table I). The mRS is a seven-point scale that progresses from 0 (no symptoms) to 6 (death) with varying levels of disability (Lubeck et al, 2016).…”